<DOC>
	<DOC>NCT00327769</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.</brief_summary>
	<brief_title>Faslodex Advanced Breast Cancer Local Chinese Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal advanced breast cancer with oestrogen receptor positive Progression under firstline antioestrogen therapy. Lifethreatening metastasis; contraindication to anastrozole &gt;2 regimens of hormonotherapy for advanced breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>anastrozole</keyword>
</DOC>